← All trials
NCT00018057
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 2, 2001
- Primary completion
- Jan 1, 2029
- Completion date
- Jan 1, 2029
- First posted
- Jul 2, 2001
- Last posted
- Dec 23, 2022
- Enrollment
- 2530
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Mental Health (NIMH)Lead sponsor
- National Institute of Mental Health (NIMH)Overall official - principal investigator
- University of MarylandCollaborator
- University of OregonCollaborator
- University of MinnesotaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.